The drug was developed by the pharmaceutical company Shifafarmed. His research began in December last year.
According to him, the drug is based on a deactivated virus developed by the Iranian pharmaceutical company Shifafarmed. The first studies on the safety and effectiveness of the vaccine began at the end of December last year.
It is noted that the country’s regulator took this step because of problems related to the import of COVID-vaccines. As stated in Tehran, the mass vaccination of Iranian residents was prevented by US sanctions.
AP informs that Iran is the most affected country in the Middle East by the coronavirus pandemic, which will now be able to increase the pace of the vaccination campaign.
Recall that in April it became known that Iran began mass production of its own COVID-vaccine. By September, the authorities intend to produce more than 30 million doses.